Orthopedic biomaterial company Graftys SA said it launched a post market surveillance patient registry examining recipients of its HBS and Quickset phosphocalcic cements.
The goal of the study is to systematically validate previous short and long term clinical results of the cements, the French orthopedic company said.
“It is important to be able to follow our patients over the middle and long term. Three centers are currently participating in the program, and data from the 1st patients have already been included in France,” study coordinator Sébastien Parratte of Marseille, France’s Hôpital de La Timone said in a press release.
The registry will document clinical results for recently approved applications of the 2 injectible cements, which were recently approved for bone marrow lesions in the knee, the company said.
“Discussions with additional international centers are underway to join the program. This registry will allow us to follow the long term outcomes for patients treated in about 20 centers and will thus become one of the most important registries in the field of injectable bone substitutes. Our plan is to use this data for publication in clinical journals,” regulatory & clinical affairs director Jean-Marc Ferrier said in prepared remarks.